Travere Therapeutics, INC Form 4 insider transactions

Chief Medical Officer Jula Inrig acquired shares and sold a portion to cover tax obligations related to vested restricted stock units.

Chief Commercial Officer Peter Heerma of Travere Therapeutics reports acquisition of stock options and sale of shares to cover tax obligations.

Christopher Cline, CFO of Travere Therapeutics, reports acquisition of stock options and restricted stock units, as well as a sale of shares to cover tax obligations.

Sandra Calvin, SVP, Chief Accounting Officer of Travere Therapeutics, reports acquisition of 13,000 shares and sale of 3,348 shares to cover tax obligations.

A Travere Therapeutics executive, William E. Rote, sold 2,437 shares of common stock at $19.46 per share under a pre-arranged 10b5-1 trading plan.

Travere Therapeutics CEO, Eric M. Dube, sold 10,736 shares of common stock at $19.46 per share on January 22, 2025, under a pre-arranged 10b5-1 trading plan.

Elizabeth E. Reed, SVP, GC & Corporate Secretary of Travere Therapeutics, sold 2,437 shares of common stock at $19.46 per share under a pre-arranged 10b5-1 trading plan.

A Travere Therapeutics director, Roy D. Baynes, exercised stock options and sold shares on January 23, 2025, according to a recent SEC filing.

Peter Heerma, Chief Commercial Officer of Travere Therapeutics, sold 1,584 shares to cover tax obligations related to vested restricted stock units.

Travere Therapeutics' Chief Financial Officer, Christopher R. Cline, sold 865 shares of common stock to cover tax obligations related to vested restricted stock units.

A Travere Therapeutics executive sold 925 shares of common stock to cover tax obligations related to vested restricted stock units.

Travere Therapeutics' Chief Medical Officer, Jula Inrig, sold shares to cover tax obligations related to vested restricted stock units.

A Travere Therapeutics executive, Sandra Calvin, exercised stock options and sold shares on December 26, 2024, under a pre-arranged 10b5-1 trading plan.

A Travere Therapeutics executive, Sandra Calvin, exercised stock options and sold a portion of the acquired shares to cover tax obligations.

Director Gary Lyons exercised stock options and sold shares of Travere Therapeutics under a pre-arranged 10b5-1 trading plan.

Director Jeffrey A. Meckler exercised stock options and sold 40,000 shares of Travere Therapeutics (TVTX) at an average price of $14.0581 on September 30, 2024.

Jula Inrig, Chief Medical Officer of Travere Therapeutics, sold 684 shares of common stock at $12.98 per share on September 10, 2024, under a pre-arranged 10b5-1 trading plan.

William E. Rote, Senior Vice President of R&D at Travere Therapeutics, sold 4,387 shares of company stock after performance stock units vested following FDA approval of FILSPARI.

Elizabeth E. Reed, SVP, GC & Corporate Secretary of Travere Therapeutics, sold 4,387 shares of common stock after performance stock units vested following FDA approval of FILSPARI.

Travere Therapeutics CEO Eric M. Dube exercised performance restricted stock units (PSUs) and sold shares to cover tax obligations after the FDA granted full approval to FILSPARI for IgA Nephropathy.

Following the FDA's full approval of FILSPARI, Travere Therapeutics' Chief Medical Officer, Jula Inrig, reports acquisition of shares through vested performance stock units and subsequent sale to cover tax obligations.

Peter Heerma, Chief Commercial Officer of Travere Therapeutics, reports acquisition of shares through vested performance stock units and a sale to cover tax obligations following FDA approval of FILSPARI.

Travere Therapeutics' CFO, Christopher R. Cline, reports acquisition and disposal of company stock following the FDA's full approval of FILSPARI for IgA Nephropathy.

Christopher R. Cline, CFO of Travere Therapeutics, sold 514 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Director Ron Squarer reported acquiring 6,500 shares of common stock and 19,500 stock options in Travere Therapeutics, Inc. on May 8, 2024.

Director John A. Orwin acquired 6,500 shares of common stock and options to purchase 19,500 shares of Travere Therapeutics, Inc. on May 8, 2024.

Director Brinkley Ruth Williams reports acquiring 6,500 shares of common stock and 19,500 stock options in Travere Therapeutics, Inc.

Director Sandra Poole reported acquiring shares and options in Travere Therapeutics under the company's equity incentive plan.

Jeffrey A. Meckler, a director of Travere Therapeutics, acquired 6,500 shares of common stock and options to purchase 19,500 shares under the company's 2018 Equity Incentive Plan.

Gary A. Lyons, a director at Travere Therapeutics, reported the acquisition of 6,500 shares of common stock and 19,500 stock options on May 8, 2024.